Do platelet GP IIIa PlA polymorphisms affect sensitivity to agonists and antiplatelet drugs in vitro?
In vitro studies show that Pl(A2)-positive platelets have a lower activation threshold and heterozygous platelets have increased sensitivity to antiplatelet drugs, which may have implications for in vivo thrombotic conditions.
Pl(A2)-positive platelets displayed a lower threshold for activation, and platelets heterozygous for Pl(A) alleles showed increased sensitivity to 2 antiplatelet drugs. These in vitro platelet studies may have relevance for in vivo thrombotic conditions.
Michelson et al. (2000) studied this question.